-
1.发明申请
公开(公告)号：WO2023080788A1
公开(公告)日：2023-05-11
申请号：PCT/NL2022/050627
申请日：2022-11-07
摘要： The invention relates to a cellular protein comprising a phenylalanine residue that replaces a tryptophan residue that is encoded by the cell's genome, to methods of identifying said cellular protein, and to a T cell epitope comprising 8-22 amino acid residues of said cellular protein. The invention further relates to a polyepitope comprising 2-50 individual T cell epitopes, a nucleic acid molecule encoding the T cell epitope, a T-cell receptor (TCR) that specifically recognizes the T cell epitope, and a pharmaceutical composition comprising the T cell epitope. The invention further relates to methods of inducing an immune response in an individual and to methods of treating an individual suffering from a tumor.
-
公开(公告)号：WO2022031169A2
公开(公告)日：2022-02-10
申请号：PCT/NL2021/050492
申请日：2021-08-04
IPC分类号： A61B17/072 , A61B34/20 , A61B90/57 , A61B17/00 , A61B90/00 , A61B17/07207 , A61B2017/00526 , A61B2017/07271 , A61B2034/2048 , A61B2034/2051 , A61B2090/3954 , A61B2090/397 , A61B2090/3983
摘要： A surgical forceps comprises a first jaw (101) and a second jaw (102), the first jaw (101) and the second jaw (102) being configured to be rotated relative to each other around an axis of rotation (104). A position sensor (105) is capable of sensing a first orientation with respect to a first axis (106) and a second orientation with respect to a second axis (107) different from the first axis (106), wherein the first axis (106) and the second axis (107) are orthogonal to the axis of rotation (104). The surgical forceps comprises a stapler (108) for stapling a tissue grasped by the surgical forceps (100) and a cutter (103) for cutting the tissue grasped by the surgical forceps (100) along a line.
-
公开(公告)号：WO2021215932A1
公开(公告)日：2021-10-28
申请号：PCT/NL2021/050273
申请日：2021-04-23
IPC分类号： C12N15/113
摘要： The invention relates to a method for increasing the efficiency of introducing a mutation using CRISPR/Cas technology. More specifically, the method is directed to preventing the occurrence of re-cutting after successful introduction of the desired mutation by introducing an inactive guide RNA. The invention further relates to use of the method in therapy and kits comprising components for carrying out the method.
-
公开(公告)号：WO2021151974A1
公开(公告)日：2021-08-05
申请号：PCT/EP2021/051915
申请日：2021-01-28
IPC分类号： A61K45/06 , A61K31/404 , A61K39/395 , C07K16/28
摘要： The invention pertains to a compound that induces aberrant splicing in a tumor cell for use in the treatment of cancer, wherein in the treatment, the compound is combined with an immune checkpoint therapy. A preferred compound is a sulphonamide, preferable an aryl-sulphonamide. The invention further pertains to a diagnostic method to identifyi a subject that benefits from immune checkpoint therapy, comprising a step of detecting the presence of a mutated splicing factor in a tumor sample.
-
公开(公告)号：WO2021080421A1
公开(公告)日：2021-04-29
申请号：PCT/NL2020/050646
申请日：2020-10-21
发明人： BERNARDS, Rene , JIN, Haojie
IPC分类号： A61K31/47 , A61K45/06 , A61K31/44 , A61K31/4709 , A61K31/506 , A61K31/517 , A61K31/5377 , A61K39/00 , A61K39/395 , A61P35/00
摘要： The invention relates to a method of treating a patient suffering from a carcinoma, especially a hepatocellular carcinoma. The methods of the invention employ a specific combination of two protein kinase inhibitors, comprising lenvatinib and an Epidermal Growth Factor Receptor (EGFR) inhibitor. The invention further relates to a pharmaceutical preparation comprising lenvatinib and an EGFR inhibitor, a kit of parts, comprising lenvatinib and an EGFR inhibitor, and to the use of the pharmaceutical preparation or the kit of parts in a method of treating a patient suffering from a hepatocellular carcinoma.
-
公开(公告)号：WO2020005063A1
公开(公告)日：2020-01-02
申请号：PCT/NL2019/050393
申请日：2019-06-26
发明人： BERNARDS, Rene , WANG, Cun
IPC分类号： A61K31/519 , A61K31/506 , A61K31/5377 , A61K45/06 , G01N33/574 , A61P35/00
摘要： The present invention relates to the field of cellular senescence and cancer therapy, more particularly to combination therapies and use thereof for the treatment of various cancers (e.g. liver cancer). Provided are combination therapy compositions comprising a CDC7 inhibitor compound, an mTOR inhibitor compound, and kit thereof, for use in the treatment of divers cancers (e.g. liver cancer, lung cancer, non-small lung cancer, colon cancer, and others), as well as for use in methods of treatment of a cancer subject (e.g. liver cancer subject) as taught herein. Also provided are methods for selecting a cancer subject suitable for treatment with the combination therapy composition of the invention.
-
7.发明申请
公开(公告)号：WO2019156568A1
公开(公告)日：2019-08-15
申请号：PCT/NL2019/050092
申请日：2019-02-12
申请人： STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS , UNIVERSITÄT BASEL
IPC分类号： G01N33/574
摘要： The present invention relates to the field of biomarker development for cancer immunotherapy with PD-1 inhibitor compounds and/or PD-L1 inhibitor compounds. Provided are assays for quantifying PD-1 expression (i.e. immunostaining intensity) in cells present in a tumor sample (i.e. intratumoral cells), which are advantageously used to identify a unique sub-population of intratumoral cells referred to herein as PD-1 T cells, which serves as a biomarker for cancer immunotherapy with PD-1 inhibitor compounds and/or PD-L1 inhibitor compounds alone or in combination with other therapeutic agents (e.g. CTLA-4 inhibitor compound, e.g. ipilimumab). The present invention also provides methods of selecting a human subject diagnosed with cancer (e.g. non-small cell lung cancer (NSCLC)) suitable for immune checkpoint therapy with agents such as PD-1 inhibitors (e.g. nivolumab) and/or PD-L1 inhibitors (e.g. atezolizumab) alone or in combination with other therapeutic agents (e.g. CTLA- 4 inhibitor compound, e.g. ipilimumab), methods for predicting responsiveness to immune checkpoint therapy with agents such as PD-1 inhibitors and/or PD-L1 inhibitors, and method of treatment of a human subject diagnosed with cancer using PD-1 inhibitors and/or PD-L1 inhibitors alone or in combination with other therapeutic agents (e.g. CTLA-4 inhibitor compound, e.g. ipilimumab).
-
公开(公告)号：WO2018167519A1
公开(公告)日：2018-09-20
申请号：PCT/GB2018/050701
申请日：2018-03-16
申请人： GENOME RESEARCH LIMITED , STICHTING HET NEDERLANDS KANKER INSTITUUT - ANTONI VAN LEEUWENHOEK ZIEKENHUIS
IPC分类号： C12Q1/48 , G01N33/574
CPC分类号： C12Q1/485 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , G01N33/5743 , G01N2333/9125 , G01N2800/52
摘要： The invention relates to the use of AXL as a biomarker for identifying responders to cancer treatment with a pharmaceutical composition comprising one or more tyrosine kinase inhibitors in combination with one or more MEK inhibitors. The invention also relates to said pharmaceutical compositions for use in the treatment of cancer and methods of treating cancer comprising said pharmaceutical compositions.
-
公开(公告)号：WO2018056824A8
公开(公告)日：2018-03-29
申请号：PCT/NL2017/050639
申请日：2017-09-25
发明人： SCHUMACHER, Antonius Nicolaas Maria , BRUMMELKAMP, Thijn Reinout , SUN , Chong , JAE , Lucas Tilmann , MEZZADRA, Riccardo Ernesto
IPC分类号： G01N33/50 , G01N33/564 , G01N33/574 , C12Q1/527
摘要： The present invention relates to the field of immunity, immune activity and more particularly to the field of "immune check points" including the PD-1/PD-L1 axis, and conditions or diseases involving PD-1/PD-L1 axis signaling. Provided are modulators of immune activity, which modulators influence the activity and/or expression of STUB1.
-
公开(公告)号：WO2018052290A8
公开(公告)日：2018-03-22
申请号：PCT/NL2017/050601
申请日：2017-09-13
发明人： VÁRADI, András , DEDINSZKI, Dóra , SZERI, Flóra Mária , BORST, Piet , VAN DE WETERING, Jan Koenraad
摘要： The invention is concerned with use of oral inorganic pyrophosphate for preventing and/or reducing tissue calcification, particularly soft tissue calcification, and/or diseases or disorders characterized by low plasma PPi levels, as, e.g., occurs in chronic kidney disease (CKD), end-stage renal disease (ESRD), generalized arterial calcification of infancy (GACI), Pseudoxanthoma elasticum (PXE), Arterial Calcification Due to Deficiency of CD73 (ACDC), Ehlers-Danlos syndrome, arteriosclerosis obliterans, venous calcifications, crystal deposition disorders, calcification resulting from neurological disorders, calcinosis universalis, calcinosis circumscripta, scleroderma, dermatomyositis, systemic lupus erythematosus, hyperparathyroidism, neoplasms, milk-alkali syndrome, hypervitaminosis D, tumoral calcinosis, hypophosphatemic rickets, ossification of the posterior longitudinal ligament of the spine, myocardial ischemia, joint calcification, heterotropic ossification of traumatized muscle, angioid streaks, diabetes mellitus type II, cardiovascular disorder, or atherosclerosis.
-
-
-
-
-
-
-
-
-
搜索结果
68 条记录 (耗时 0.027 秒)
